Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma

Inclusion Criteria:

   - Diagnosis of neuroblastoma or ganglioneuroblastoma by histology or as evidenced by the
   presence of clumps of tumor cells in bone marrow and elevated catecholamine
   metabolites in urine meeting any of the following criteria:

      - Patients with newly diagnosed neuroblastoma with International Neuroblastoma
      Staging System (INSS) stage 4 disease are eligible with the following:

         - MYCN amplification (i.e., greater than four-fold increase in MYCN signals as
         compared to reference signals), regardless of age or additional biologic
         features

         - Age > 18 months (i.e., > 547 days) regardless of biologic features

         - Age 12-18 months (i.e., 365-547 days) with none of the following three
         favorable biologic features (i.e., non-amplified MYCN, favorable pathology,
         and deoxyribonucleic acid [DNA] index > 1)

      - Patients with newly diagnosed neuroblastoma with INSS stage 3 are eligible with
      the following:

         - MYCN amplification (i.e., greater than four-fold increase in MYCN signals as
         compared to reference signals), regardless of age or additional biologic
         features

         - Age > 18 months (i.e., > 547 days) with unfavorable pathology, regardless of
         MYCN status

      - Patients with newly diagnosed INSS stage 2a or 2b with MYCN amplification (i.e.,
      greater than four-fold increase in MYCN signals as compared to reference
      signals), regardless of age or additional biologic features

      - Patients with newly diagnosed INSS stage 4s with MYCN amplification (i.e.,
      greater than four-fold increase in MYCN signals as compared to reference
      signals), regardless of additional biologic features

      - Patients >= 365 days initially diagnosed with INSS stage 1, 2, or 4S and who
      progressed to a stage 4 without interval chemotherapy

         - Must have been enrolled on COG-ANBL00B1

   - Creatinine clearance or radioisotope glomerular filtration rate ? 70mL/min OR serum
   creatinine based on age/gender as follows:

      - 1 month to < 6 months: 0.4 mg/dL

      - 6 months to < 1 year: 0.5 mg/dL

      - 1 to < 2 years: 0.6 mg/dL

      - 2 to < 6 years: 0.8 mg/dL

      - 6 to < 10 years: 1 mg/dL

      - 10 to < 13 years: 1.2 mg/dL

      - 10 to < 16 years: 1.5 mg/dL (male), 1.4 mg/dL (female)

      - >= 16 years: 1.7 mg/dL (male), 1.4 mg/dL (female)

   - Total bilirubin ? 1.5 times upper limit of normal (ULN) for age

   - Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 10 times ULN for
   age

   - Not pregnant or nursing

   - Negative pregnancy test

   - Shortening fraction >= 27% by echocardiogram (ECHO) OR left ventricular ejection
   fraction (LVEF) >= 50% by radionuclide angiogram

   - No known contraindication (e.g., size, weight or physical condition) to peripheral
   blood stem cell collection

   - No prior systemic therapy except for localized emergency radiation to sites of
   life-threatening or function-threatening disease

   - No more than one course of chemotherapy per low- or intermediate-risk neuroblastoma
   therapy prior to determination of MYCN amplification and histology